Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).
7496
Cubist/Calixa Deal the Latest in a String of Biotech Buyouts
Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.
Burrill Report: Biotech Innovation Gets the Cash
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
Ironwood Receives $75M from Astellas for IBS Drug
The Cambridge, Mass.-based company has signed a $75 million deal with Astella Pharmaceuticals to market Ironwood’s IBS drug in Asia.
FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
Zogenix, Astellas Announce Positive Data for Unique Migraine Therapy
Zogenix, a pharmaceutical company specializing in the treatment of chronic pain, and Astellas Pharma have announced positive clinical trial data from two studies of their needle-free migraine treatment system.